Perennial Investment Advisors LLC Sells 2,291 Shares of Pfizer Inc. $PFE

Perennial Investment Advisors LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,631 shares of the biopharmaceutical company’s stock after selling 2,291 shares during the quarter. Perennial Investment Advisors LLC’s holdings in Pfizer were worth $549,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer in the 1st quarter worth approximately $27,000. Curio Wealth LLC grew its holdings in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the last quarter. Bayforest Capital Ltd bought a new stake in Pfizer in the first quarter worth about $28,000. Harbor Asset Planning Inc. bought a new position in shares of Pfizer during the second quarter valued at approximately $29,000. Finally, WPG Advisers LLC purchased a new position in Pfizer during the 1st quarter valued at $35,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 price objective on shares of Pfizer in a research report on Wednesday, November 5th. Scotiabank initiated coverage on shares of Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price on the stock. Sanford C. Bernstein restated a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $28.28.

Pfizer Stock Performance

Shares of Pfizer stock opened at $25.45 on Wednesday. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The company has a 50-day simple moving average of $24.82 and a two-hundred day simple moving average of $24.46. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market capitalization of $144.70 billion, a PE ratio of 13.54, a P/E/G ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is presently 100.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.